MS News: May 2017

2017 Meeting American Academy of Neurology (AAN)

• Aubagio in people at risk of MS
• Cladribine
• Gilenya
• Lemtrada long-term data
• Lemtrada and black people
• Opicinumab
• Siponimod
• Importance of early effective treatment
• NEDA challenged
• Measuring disease activity in progressive MS
• Predicting risk of conversion to SPMS
• Risk factors for MS in children and teenagers

Research

1. Molecule can help to repair myelin in mice
   

Clinical Trials

1. Laquinimod trial unsuccessful
2. Simvastatin trial planned for secondary progressive multiple sclerosis
3. Ozanimod trail results
4. Biotin trial planned
5. Multi-million pound trial to investigate if statins could become MS treatment

Treatment News

1. First treatment licensed for primary progressive MS in the US
2. Gilenya effect on relapses
3. Fampridine granted full licence
4. Safety of beta interferon
5. Sativex in the UK
6. Relapsing-remitting MS: Alemtuzumab boosts outcomes for black patients

General news

1. New tool to improve disability benefits test
2. Next UK Government must commit: no more cuts to disability benefits
3. Rise in avoidable hospital admissions for people with MS
4. A new manifesto for neurology services in England
5. Contraceptive safety in MS
6. Carers and the impact of MS
7. MS in America

Mental & Emotional Health

1. Assisted suicide rethink

Diet

1. Weight and MS severity
2. Children, vitamin D and obesity

Lifestyle

1. Smoking and MS

News posted on Barts MS Blog, with thanks to Gavin Giovannoni and his team:

1. #BrainHealth: a brain health guide for nurses
2. #ClinicSpeak: What does the NHS crisis mean for pe…
3. #ClinicSpeak: developing a personal relationship w…
4. #ClinicSpeak: delayed MS diagnosis
5. #ClinicSpeak: Day-4 post cyberbombing
6. #ClinicSpeak: what is CMV reactivation disease?
7. #ClinicSpeak: are you planning to go abroad for HS…
8. #ClinicSpeak: real world evidence teriflunomide
9. #ClinicSpeak & #ResearchSpeak: daclizumab’s impact…
10. #ClinicSpeak & #ResearchSpeak: Graves’ eye disease…
11. #ClinicSpeak & #BrainHealth: do we really need to …
12. #ClinicSpeak & #BrainHealth: policy document under…
13. #NeuroSpeak: DMF as a second-line agent or not
14. #NeuroSpeak: more on ocrelizumab in PPMS
15. #NewsSpeak: Jet-lag and the CMSC 2017 meeting in N…
16. #NewsSpeak: ECTRIMS NEWSLETTER May 2017
17. #NewsSpeak: MS-STAT2 finally takes-off
18. #NewsSpeak: third laquinimod trial in RRMS fails
19. #PatientSpeak: I have primary progressive MS ……..
20. #PlainEnglish: Targeting the “virus factory” to st…
21. #PoliticalSpeak: on-label teriflunomide vs. off-la…
22. #ResearchSpeak: MS is one disease
23. #ThinkSpeak: social medicine and meat
24. #ThinkSpeak: immune rejuvenation therapy
25. #ThinkSpeak & #AAN2017: musings on my return from …
26. #ThinkSpeak & #ClinicSpeak: do PPMSers need a DMT?…
27. #ThinkSpeak & #PolitcalSpeak: a balancing act
28. AAN-ABN
29. AAN2017: BBC could be used to advertise……healt…
30. T regs
31. MS isn’t caused by antibodies to myelin
32. Damaging Cholesterol
33. CD20 antibodies deplete EBV
34. First case of PML on Ocrelizumab reported
35. GABA controls oligodendrocytes
36. GABA and Remyelination-Its Confusing I know but no…
37. Be A Hero Ocrevus
38. What is your Choice?
39. Steroids and relapse route does not matter
40. MS Genes why they may not always cause MS
41. Overdosing with Natalizumab
42. Are we there yet with JCV testing?
43. Blast from the Past…Memory B cells depleted by H…
44. BARTS HEALTH NEWS UPDATE
45. DMF kills Memory B cells
46. Dimethyl fumarate and Memory B cells
47. BBB permeability is formed by slow rate of movemen…
48. Imaging T cells in real time is Grizzly
49. How do statins work in Secondary Progressive MS
50. New outcomes for Progressive MS in a Year
51. Heart Failure during Relapse

©Willeke Van Eeckhoutte and Ireland, Multiple Sclerosis & Me, 2011-2017. Unauthorised use and/or duplication of this material without express and written permission from this blog’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Willeke Van Eeckhoutte and Ireland, Multiple Sclerosis & Me with appropriate and specific direction to the original content.